Citius Oncology, Inc. Accrued Liabilities, Current
Citius Oncology, Inc. (CTOR) had Accrued Liabilities, Current of $25.84 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-08-14
- 2026-06-30: Accrued Liabilities, Current $25.84M.
- 2026-03-31: Accrued Liabilities, Current $24.06M.
- 2025-12-31: Accrued Liabilities, Current $4.52M.
- 2025-09-30: Accrued Liabilities, Current $4.09M.
| Period end | Accrued Liabilities, Current | Accrued Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $25.84M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $24.06M 10-Q · filed 2026-05-15 | |
| 2025-12-31 | $4.52M 10-Q · filed 2026-02-13 | |
| 2025-09-30 | $4.09M 10-Q · filed 2026-08-14 | |
| 2025-06-30 | $8.46M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | $8.72M 10-Q · filed 2025-05-14 | |
| 2024-12-31 | $6.23M 10-Q · filed 2025-02-14 | |
| 2024-06-30 | $485.75K 10-Q · filed 2024-08-09 | |
| 2024-03-31 | $488.24K 10-Q · filed 2024-05-20 | |
| 2023-12-31 | $375.89K 10-Q · filed 2024-08-09 | |
| 2023-09-30 | $259.07K 10-K · filed 2024-12-27 | $383.70K 10-Q · filed 2023-11-20 |
| 2023-06-30 | $108.90K 10-Q · filed 2023-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |